SOLVD Health Announces FDA Approval for AvertD® Blood Sample Collection
SOLVD Health has received FDA approval to expand the sample collection for its AvertD® genetic test to include venous whole blood. This expands the availability of AvertD®, the first and only FDA-approved test designed to assess the genetic risk of opioid use disorder (OUD) before a patient receives their first oral opioid prescription for acute pain. The test operates as a qualitative genotyping tool.
SAN DIEGO–(BUSINESS WIRE)–SOLVD Health, a privately held company focused on preventing disease through actionable and personalized health information, today announced broad availability of AvertD® following FDA approval to expand sample collection to include venous whole blood. AvertD is the first and only FDA‑approved genetic test indicated to assess genetic risk of opioid use disorder (OUD) prior to first exposure to oral opioids for acute pain. AvertD is a qualitative genotyping test that